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ARTICLE
Cyclooxygenase inhibitors impair CD4 T cell
immunity and exacerbate Mycobacterium
tuberculosis infection in aerosol-challenged mice
Rasmus Mortensen 1, Helena Strand Clemmensen 1, Joshua S. Woodworth 1, Marie Louise Therkelsen1,
Tehmina Mustafa2, Kristian Tonby3, Synne Jenum3, Else Marie Agger1, Anne Ma Dyrhol-Riise3,4,5 &
Peter Andersen1,6
Tuberculosis, caused by infection with Mycobacterium tuberculosis (Mtb), kills over 1.6 million
people each year despite availability of antibiotics. The increase in drug resistant Mtb strains
is a major public health emergency and host-directed therapy as adjunct to antibiotic
treatment has gained increased interest. Cyclooxygenase inhibitors (COXi) are frequently
used drugs to alleviate tuberculosis related symptoms. Mouse studies of acute intravenous
Mtb infection have suggested a potential beneﬁt of COXi for host-directed therapy. Here we
show that COXi treatment (ibuprofen and celecoxib) is detrimental to Mtb control in different
mouse models of respiratory infection. This effect links to impairments of the Type-1 helper
(Th1) T-cell response as CD4 T-cells in COXi-treated animals have signiﬁcantly decreased
Th1 differentiation, reduced IFNγ expression and decreased protective capacity upon adoptive
transfer. If conﬁrmed in clinical trials, these ﬁndings could have major impact on global health
and question the use of COXi for host-directed therapy.
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Tuberculosis (TB), caused by Mycobacterium tuberculosis(Mtb), constitutes one of the biggest global health pro-blems of our time. An estimated 10 million new cases and
1.6 million deaths in 2017 makes TB the leading infectious cause
of death and more than one fourth of the world’s population are
latently infected1. Even for drug sensitive TB, the global cure rate
is <85% and the availability of effective therapy is further threa-
tened by the growing epidemic of multi-drug resistant Mtb
strains.
Host-directed therapy, i.e. modulation of speciﬁc host immune
pathways, including those that impact inﬂammation and immuno-
pathology, constitutes an attractive avenue with potential for treat-
ment of both drug sensitive and multi-drug resistant TB. Among the
already approved medicines, non-steroidal anti-inﬂammatory drugs
(NSAIDs), including cyclooxygenase inhibitors (COXi), have been
proposed as candidates for host-directed therapy due to their
potential to reduce inﬂammation and hereby resolve host-meditated
immune pathology2–4. In addition, COXi are also commonly used
drugs to alleviate TB related symptoms.
COXi target either one or both isoforms of the COX enzyme
(COX-1 and COX-2), which are involved in the synthesis of pros-
taglandins, most notably PGE2 that is a potent immune modulator5.
During the establishment of Mtb infection, PGE2 appears to be
essential for bacterial control, possibly by promoting apoptosis of
infected macrophages and counteracting production of type I
interferons, whereas elevated PGE2 levels at later stages seems to
promote disease progression6–9. Initial animal studies using COXi in
aerosol-infected Balb/c mice showed diverging results; there was no
observed effect of ibuprofen or acetylsalicylic acid (aspirin) as stand-
alone treatment, but aspirin was found to antagonize antibiotic
treatment with isoniazid whereas ibuprofen/aspirin enhanced pyr-
azinamide treatment10,11. However, more recent studies have con-
vincingly shown that treatment with ibuprofen or aspirin alone
reduces the bacterial burden and prolongs survival after intravenous
(i.v.) infection of highly TB-susceptible C3HeB/FeJ mice12–14. In this
model, mice rapidly developed severe lung pathology and inﬂam-
mation, which was reduced by COXi13. While this model reﬂects
some aspects of human disease (e.g. development of necrotic/
hypoxic lesions)15,16, we speculated whether this beneﬁcial inﬂuence
was consistent in other less pathology prone animal models
mimicking respiratory Mtb infection. The aim of the present study
was therefore to investigate the effect of COXi in a standardized low-
dose aerosol infection model, where mice acquire a stable chronic
infection that is CD4 T cell dependent17. Not only does aerosol
infection more accurately reﬂect the natural respiratory infection
route in humans, but establishment of a stable infection also allows
investigation of long-term treatment effects.
In this study, we show for the ﬁrst time that treatment with COXi
(celecoxib and ibuprofen) can increase the bacterial burden after
aerosol infection. When the infection route is changed from aerosol
to i.v., COXi treatment decreases inﬂammation and reduces the
bacterial burden in the lung, as previously reported. In the aerosol
model, there is little or no impact on inﬂammation or recruitment of
innate cells. Instead, COXi treatment impairs formation of immune
memory, reduces Type 1 helper T cell (Th1) function/differentiation
and diminishes the protective capacity of CD4 T cells. Given that
COXi, and NSAIDs in general, are some of the most used drugs in
clinical practice, this should be further investigated. If COXi pose a
risk of TB progression in Mtb infected subjects, it could have major
impact on the global TB epidemic and question the relevance of
these drugs as candidates for host-directed therapy.
Results
COXi treatment exacerbates Mtb aerosol infection in CB6F1
mice. Previous publications have demonstrated that COXi
treatment during Mtb infection can improve outcome and reduce
bacterial burden12–14. In the present study, we investigated this in
more detail using a standardized low dose TB aerosol model in
CB6F1 mice. We initially evaluated the effects of celecoxib, a
speciﬁc COX-2 inhibitor that can be formulated efﬁciently into
the animals’ chow18. This circumvents the need to perform daily
oral administrations and eliminates the bias that treated animals
are stressed by extensive handling. Mice were challenged with
~25–50 CFU Mtb Erdman and put on chow containing 500 ppm
celecoxib after 4 weeks (peak of infection). We found that
celecoxib-treated mice had higher bacillary burdens in lungs and
spleen after both 2 and 8 weeks of treatment, corresponding to
week 6 and 12 of the infection, respectively (Fig. 1a). Importantly,
there was no difference in animal weight between the two groups,
indicating that addition of celecoxib to the chow did not affect
feeding habits (Fig. 1b). We further investigated soluble proin-
ﬂammatory cytokines in plasma and lung homogenates (IL-1β,
KC/GRO, TNFα, IL-6, IL-12p70, and IFNγ) as well as pulmonary
inﬂux of myeloid-derived cells 2 weeks into COXi treatment
(week 6 of infection). In previous studies, COXi reduced
inﬂammation and neutrophilic inﬁltration12–14, but we found no
difference in the number of neutrophils, inﬂammatory mono-
cytes, macrophages/monocytes or alveolar macrophages/dendritic
cells (DCs) in the lungs (Fig. 1c, d and Supplementary Fig. 1).
There was a tendency that the expression of MHCII and CD86
was higher on CD11b+CD11c+ cells in the celecoxib-treated
animals, which might be explained by the higher bacterial load
(Supplementary Fig. 2A). In general, cytokine levels were low, and
there were no differences between the two groups on any of the
cytokines that were investigated in both plasma and lung
homogenates (Supplementary Fig. 2B, C).
In summary, using our standardized aerosol Mtb infection
model in CB6F1 mice, we found that celecoxib treatment
increased bacterial burden. This was not associated with
differences in pulmonary inﬂammation or inﬁltration of innate
immune cells, suggesting that the treatment effect was not linked
to dysregulation of the innate inﬂammatory response.
The COXi treatment effect is dependent on route of infection.
Given the unexpected increased bacterial growth after celecoxib
treatment in our ﬁrst experiment, we assessed the robustness of
the observation. As previous studies utilized the non-selective
COXi, ibuprofen and aspirin, in an i.v. Mtb infection model, we
initiated a series of experiments to test whether the treatment
outcome was dependent on infection route and/or drug. First, we
carefully reproduced the data of Vilaplana et al.12 by showing that
a 1-week course of 80 mg/day oral ibuprofen lowered the pul-
monary bacterial burden after Mtb H37Rv i.v. infection in the
highly susceptible C3HeB/FeJ mice (Fig. 2a, left). Secondly, we
demonstrated that this effect could be extrapolated to a more
Mtb-resistant mouse strain, as the same result was obtained with
CB6F1 mice infected i.v. with Mtb Erdman (Fig. 2a, right).
Interestingly, and in contrast to the aerosol/celecoxib infection
model, ibuprofen treatment after i.v. infection signiﬁcantly
decreased lung inﬁltration of neutrophils as well as IL-6 (Fig. 2b, c
and Supplementary Fig. 3, p= 0.028 and p < 0.0001).
Having conﬁrmed that ibuprofen had a positive effect in the
i.v. infection model, we tested whether this also was the case in
the aerosol infection model. For this, we used an experimental
design that mirrored the study in Fig. 1, but replaced celecoxib
with ibuprofen. CB6F1 mice were infected via the aerosol route
and 4 weeks into the infection, they were put on a course of
80 mg/day oral ibuprofen. 8 weeks after treatment (week 12 of
the infection), animals were sacriﬁced and Mtb bacilli were
enumerated by plating organ homogenates. Similar to the ﬁrst
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experiment with celecoxib, we found that ibuprofen signiﬁ-
cantly increased the bacterial burden in both the lungs and the
spleen (Fig. 2d, p= 0.0098 and p= 0.024). Consistent with the
celecoxib-treatment data (Fig. 1), ibuprofen had no impact on
the inﬁltration of neutrophils (Fig. 2e). Finally, to explore
whether the treatment outcome was dependent on bacterial
load, we challenged CB6F1 mice with a high-dose Mtb Erdman
infection by the aerosol route. Mice were put on oral ibuprofen
at week 3 and monitored for 1 week using a validated clinical
scoring system (see materials and methods). At week 4, 27/32
animals in the ibuprofen group met the pre-deﬁned humane
endpoints for euthanization compared to 16/32 in the control
group (Fig. 2f). Together, this indicated that the negative
treatment outcome of COXi was dependent on infection route
(rather than bacterial load in the model).
In summary, we showed that the negative impact of COXi on
Mtb control after aerosol infection was experimentally robust, as
the same results were obtained with both celecoxib and ibuprofen
as well as after both low- and high-dose Mtb challenge. The effect
of COXi treatment appears to depend on the infection model, as
ibuprofen treatment decreased inﬂammation and bacterial
burden when the infection was initiated via the i.v. route.
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Fig. 1 Celecoxib treatment exacerbates Mtb aerosol infection. a Female CB6F1 mice of 5–8 weeks of age were infected with ~25–50 CFU Mtb Erdman by
the aerosol route (week 4 (n= 4), week 6 (n= 6), week 12 (n= 8)). 4 weeks into the infection, mice were fed with normal chow or chow containing
500 ppm celecoxib. Mtb bacilli were enumerated by plating lung and spleen homogenates 2 and 8 weeks later (week 6 and 12 of the infection). b Animal
weight was monitored at week 6 (n= 16) and week 12 (n= 8) to ensure that the observed differences were due to treatment effects and not because of weight-
loss from altered feeding habits. c Two weeks after treatment (week 6 of the infection), the pulmonary inﬂux of myeloid-derived cells was determined
by staining lung cells for CD11b, CD11c, Ly-6C, Ly-6G, and MCHII. Neutrophils were deﬁned as CD11b+/Ly-6Cdim/Ly-6G+, inﬂammatory monocytes as
CD11b+/Ly-6Chigh/Ly-6G−. Gating on Ly-6C−/Ly-6G−CD11b+ cells, macrophages/monocytes (Mø/Mo) were deﬁned as CD11b+/MHCII+/CD11c− and a
mixed population of alveolar macrophages/dendritic cells (Alv. Mø/DCs) was deﬁned as CD11b+/MHCII+/CD11c+. d Individual mice were analyzed for the
number of neutrophils, inﬂammatory monocytes, macrophages and alveolar macrophages/dendritic cells in the lung 2 weeks into the treatment (n= 6). Bars
represent mean ± SEM and p values were calculated with an unpaired two-tailed t-test comparing treated and non-treated animals
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Celecoxib impairs immune memory and affects CD4 T cell
phenotype. Given that treatment with celecoxib and ibuprofen
decreased host resistance following aerosol infection, without
affecting inﬂammation/recruitment of innate cells, we wanted to
determine whether the effect was long-lived. For this, we applied
an Mtb re-infection model, where CB6F1 mice were treated with
celecoxib for 8 weeks as previously followed by a 12-week anti-
biotic course of isoniazid/rifabutin. Subsequently, the mice were
rested for 2 weeks prior to aerosol Mtb re-infection (Fig. 3a). Mice
that were treated with celecoxib during the initial infection had
signiﬁcantly increased bacterial burdens in lungs (Fig. 3b) and
spleen (Supplementary Fig. 4A) when their second infection
progressed from week 3 to week 6, indicating that the COXi-effect
was long-lasting and independent on ongoing celecoxib treat-
ment (p < 0.0001 and p = 0.0015, respectively). There was a slight
tendency that the mice in the celecoxib group also had larger
changes in histopathology at week 6, but this was not statistically
signiﬁcant (Supplementary Fig. 4B, p= 0.28). As there is ample
evidence that COXi and/or PGE2 concentrations regulate indu-
cible nitric oxide synthase (iNOS) in macrophages6,19–21, we
investigated whether the increased bacterial burden in the cel-
ecoxib group was associated with compromised iNOS expression.
Contrary to the expectation, stained tissue sections of lungs
revealed that iNOS expression was elevated in the celecoxib
group, correlating with bacterial burden, which suggests that the
treatment did not affect antigen-driven iNOS expression (Sup-
plementary Fig. 4C). We then examined whether the initial COXi
treatment affected the CD4 T cell recall response and found that
the number of Mtb-speciﬁc CD4 T cells measured by intracellular
cytokine staining (ICS) was not signiﬁcantly different between
groups at any time point (Fig. 3c, p= 0.21 and p= 0.10).
The impaired control of re-infection in mice treated with
celecoxib during the initial infection suggested the involvement of
an altered adaptive immune response. Given that the magnitude
of the CD4 T cell recall response was unaltered during re-
infection, we hypothesized that celecoxib treatment induced
changes in the phenotype/quality of the T cell response. To test
this, we analyzed the CD4 T cell response in animals receiving
celecoxib treatment during the ﬁrst infection (Fig. 3d). There was
a small, but detectable, decrease in the number of CD4 T cells in
the lungs of celecoxib-treated mice at week 6 (Fig. 3e) but this
difference was gone by week 12. Throughout the infection, there
was no difference in the frequency of ESAT-6 responsive CD4
T cells, indicating that T cell priming and/or maintenance was
not obstructed by the celecoxib treatment (Fig. 3e). Combinator-
ial analysis of the cytokine producing CD4 T cells also revealed
i.v. Mtb C3HeB/FeJ
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Fig. 2 The COXi treatment effect is dependent on route of infection, not a speciﬁc COX1/2 inhibitor. a Female C3HeB/FeJ or CB6F1 mice of 6 to 8-weeks of
age were infected by intravenous (i.v.) injection of 5 × 104 Mtb H37Rv or Erdman respectively. After 3 weeks, the animals were put on a 1-week course of
80mg/day oral ibuprofen before enumerating Mtb bacilli in the lungs (n= 13). b The frequency of neutrophils in the lungs of C3HeB/FeJ mice (n= 4) was
determined by ﬂow cytometry gating on CD11b+/Ly-6G+ cells 1 week after treatment. c Soluble IL-6 was measured along with other pro-inﬂammatory
cytokines (Supplementary Fig. 3) by multiplex analysis of lung homogenates of C3HeB/FeJ mice after 1 week of treatment (n= 4). For this analysis, q
values (adjusted p values) were calculated with an ANOVA followed by the Benjamini-Hochberg method to control the false discovery rate during multiple
comparisons. d 6 to 8-week-old female CB6F1 mice were infected with a low dose of ~25–50 CFU Mtb Erdman by the aerosol (AE) route and put on a
course of 80mg/day oral ibuprofen at week 4 of the infection (as in Fig. 1). After 8 weeks of treatment (week 12 of the infection), Mtb bacilli were
enumerated in both lungs and spleen by plating organ homogenates (n= 8). Data is shown from one out of two independent experimentswith n= 8 and
n= 6, respectively. e Two weeks into the treatment (week 6 of the infection) the frequency of neutrophils in the lungs was determined as before (data
from one representative experiment, n= 8). f 6 to 8-week-old female CB6F1 mice were infected with a high-dose of ~150–300 CFU Mtb Erdman by the
aerosol (AE) route and put on a course of 80mg/day oral ibuprofen at week 3 of the infection. Mice were monitored individually for 1 week and euthanized
when they reached pre-deﬁned humane endpoints. The p value was calculated using a chi-square test. Bars represent mean ± SEM and p values were
calculated with an unpaired two-tailed t-test comparing treated and non-treated animals (unless otherwise indicated)
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-019-0530-3
4 COMMUNICATIONS BIOLOGY |           (2019) 2:288 | https://doi.org/10.1038/s42003-019-0530-3 | www.nature.com/commsbio
that the cytokine expression proﬁle was identical in treated and
untreated animals (Supplementary Fig. 4D).
Recent literature from murine studies supports that CD4
T cells expressing KLRG1 are less efﬁcient at homing to the
infected tissue, which is associated with a less protective T cell
phenotype22–24. We therefore explored whether the negative
effect of celecoxib treatment was associated with KLRG1
expression and/or impaired CD4 T cell homing, but found no
differences on either parameter (Fig. 3f, Supplementary Fig. 4E
and Supplementary Fig. 5). Finally, since PGE2 is known to
inﬂuence Th1 differentiation25, we investigated whether celecoxib
treatment altered cellular expression of the Th1-fate regulating
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Fig. 3 Celecoxib impairs immune memory and affects CD4 T cell phenotype. a 6 to 8-week-old female CB6F1 mice were infected with ~25–50 CFU Mtb
Erdman by the aerosol route and fed with celecoxib chow for 8 weeks as previously (week 4–12). At week 10, mice were put on antibiotic treatment with
rifampicin/isoniazid for 12 weeks to clear the infection (week 10–22). After a 2-week rest to wash out the antibiotics, mice re-infected with 50–100 CFU
Mtb Erdman by the aerosol route. b Mtb bacilli were enumerated in the lungs at week 3 (n= 10) and 6 (n= 16) of the re-infection by plating organ
homogenates. c The number of cytokine positive CD4 T cells (producing any combination of IFNγ, TNFα or IL-2, see and Supplementary Fig. 5) was
determined by ICS of lung cells stimulated with overlapping ESAT-6 peptides (n= 6). d Female CB6F1 mice were infected with ~25–50 CFU Mtb Erdman by
the aerosol route and fed with celecoxib chow as previously (same experiment as in Fig. 1). e The total number of CD4 T cells as well as the frequency of
cytokine producing CD4 T cells (IFNγ, TNFα or IL-2) was determined by ICS of lung cells stimulated with overlapping ESAT-6 peptides (week 0 n= 2, week
6 n= 6, week 12 n= 8). f At week 12, the ability of CD4 T cells to home to infected tissue was assessed by enumerating the CD4 T cells that were not
stained by i.v. injection of a labeled CD45 antibody (IV−). g The Th1 differentiation status of activated CD4 T cells (CD44hi) was assessed in both cytokine
producing (red) and non-producing (grey) T cells by staining for the linage-speciﬁc transcription factor, T-bet (data show a concatenation of every animal
in each group). h (left) the frequency of T-bet+ CD4 T cells in the cytokine producing population of each animal, (right) T-bet expression measured by
mean ﬂuorescence intensity (MFI) of the population of T-bet+ CD4 T cells (n= 6). Bars represent mean ± SEM and p values were calculated with an
unpaired two-tailed t-test comparing treated and non-treated animals
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transcription factor, T-bet (Fig. 3g). Indeed, when we analyzed
the CD44hi T cell population (grey) and the cytokine producing
T cells after Mtb antigen stimulation (red), it was evident that
celecoxib treatment signiﬁcantly decreased both the frequency of
T-bet expressing CD4 T cells as well as the T-bet expression level
(Fig. 3g, h, p= 0.0030 and p= 0.0028, respectively).
In summary, we demonstrated that celecoxib treatment during
Mtb infection of CB6F1 mice impaired formation of memory
immunity with little or no inﬂuence on the magnitude of the CD4
T cell response. Instead, we observed a signiﬁcant drop in the
expression of T-bet, indicating that COXi inﬂuence Th1
differentiation and/or effector-function of CD4 T cells.
Celecoxib diminishes the protective capacity of CD4 T cells. To
investigate whether the celecoxib-mediated decrease in Th1 dif-
ferentiation was associated with reduced effector function and/or
protective capacity, we performed an adoptive transfer study with
cells from either celecoxib-treated animals or untreated control
animals (Fig. 4a). Wild type C57BL/6 donor mice were aerosol
infected with Mtb and treated for 4 weeks with celecoxib before
CD4 T cell isolation from spleen and lymph nodes (LNs; tra-
cheobronchial and mediastinal). At this time point, the frequency
of Mtb antigen speciﬁc CD4 T cells in the two groups was similar
and the T-bet expression was decreased in the celecoxib animals,
as previously observed (Fig. 4b, c). This was associated with a
decreased IFNγ expression (Fig. 4d). We also analyzed expression
of FoxP3 (Tregs), RORγt (Th17) and GATA3 (Th2) and found
no effect on any these markers, indicating that the celecoxib
treatment speciﬁcally affected Th1 cells in our model (Supple-
mentary Fig. 6A, B).
After characterizing the donor cells, 9.5 × 106 CD4 T cells/
mouse were transferred into C57BL/6 TCRα−/− recipients that
were infected 7 days prior to cell transfer. Six weeks into the
infection there was no signiﬁcant difference in the frequency of
cytokine producing CD4 T cells between recipient groups (Fig. 4e,
p= 0.15). However, the phenotype of decreased T-bet expression
was intact post transfer, which was associated with signiﬁcantly
reduced IFNγ expression of the CD4 T cells (Fig. 4f, p= 0.0022).
Finally, we enumerated Mtb bacilli in recipient mice. Similar to
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Fig. 4 Celecoxib reduce IFNγ expression and diminish the protective capacity of CD4 T cells. a WT C57BL/6 donor mice were infected with ~25–50 CFU
Mtb Erdman by the aerosol route and treated for 4 weeks with celecoxib (week 4–8) before purifying CD4 T cells from pooled spleen and tracheobronchial/
mediastinal lymph nodes. A total of 9.5 × 106 puriﬁed CD4 T cells/mouse were transferred into B6.129S2-Tcratm1Mom recipients (TCR−/−) that were
infected 7 days prior to cell transfer. b At the day of transfer, the pool of puriﬁed donor cells were characterized for the frequency of antigen speciﬁc
CD4 T cells by ESAT-64-17 tetramer staining as well as expression of T-bet (c) and IFNγ (d) in CD4 T cells producing any combination of IFNγ, TNFα or IL-2
after stimulation with overlapping ESAT-6 peptides. e Five weeks after cell transfer (week 6 of the infection), the frequency of cytokine producing
CD4 T cells in the lungs of the recipient mice was determined by ICS after ESAT-6 peptide stimulation (n= 8). f The cytokine producing CD4 T cells were
further characterized based on the expression of T-bet and IFNγ. g Mtb bacilli were enumerated in the recipient animals at week 3 and 6 of the infection by
plating lung homogenates (n= 8). All the TCR−/− mice in the control group that did not receive any CD4 T cells met the humane endpoints for euthanasia
before week 6. Bars represent mean ± SEM and p values were calculated with an unpaired two-tailed t-test comparing treated and non-treated animals
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the re-infection experiment (Fig. 3b), we found that mice
receiving CD4 T cells from celecoxib-treated animals had a
higher lung bacterial burden at week 6 of the infection, indicating
that the long-term protective capacity of the CD4 T cells was
compromised by the celecoxib treatment (Fig. 4g). Together with
the previous experiments, this formally demonstrates that COXi
treatment during Mtb aerosol infection can inﬂuence Th1
differentiation and/or effector-function of CD4 T cells and
diminish their protective capacity.
Discussion
The outcome of Mtb infection is highly dependent on the
inﬂammatory balance mediated by innate and adaptive compo-
nents of the immune response and host-directed therapy are
exploring strategies to both suppress and augment immune
functions3,26. COXi are commonly used to treat TB related
symptoms, but have also been suggested as host-directed therapy
due to their immune-modulating properties2,4. Recent murine
studies support that COXi during Mtb infection can alleviate
excessive inﬂammation and limit neutrophil inﬁltration resulting
in improved outcome12–14. Notably, these studies assessed COXi
treatment after i.v. infection of highly susceptible C3HeB/FeJ
mice, whereas the primary goal of the present study was to
examine the effects of COXi treatment in a standardized low dose
aerosol infection model in the less Mtb susceptible CB6F1 mice.
Contrary to our expectations, we found that animals treated with
celecoxib or ibuprofen had increased bacterial burden compared
to untreated control animals. After high-dose aerosol challenge,
ibuprofen decreased survival. We hypothesized that the dis-
crepancy between our result and the previous studies could be
due to different infection routes and indeed, we observed that
ibuprofen treatment lowered the bacterial burden when admi-
nistered after i.v. infection. In agreement with the previous stu-
dies, ibuprofen decreased pro-inﬂammatory cytokines and
neutrophil inﬁltration after i.v. infection, whereas we observed no
effect of COXi on these parameters after aerosol infection. The
discrepancy between the results of the aerosol and i.v. models
could be caused by several differences in the experimental
infection approach. One of the major differences being that the
inoculum is over 100–1000 times higher in the i.v. model com-
pared to the aerosol model. Although the resulting bacterial
burden in the lung eventually reaches the same level in the two
models27, delivery of high bacterial numbers directly into the
blood stream would cause immediate dissemination to immune-
competent organs, like the spleen, resulting in rapid systemic
inﬂammation. In contrast, in the aerosol model only a few bac-
teria are delivered to the lungs, where they are taken up by
alveolar macrophages, which have a less inﬂammatory proﬁle
compared to monocytes and monocyte-derived macrophages that
predominate other organs28–30. Therefore, speculating that the
accelerated systemic inﬂammation in the i.v. model would favor a
beneﬁcial role of anti-inﬂammatory treatment compared to the
aerosol model seems reasonable. In addition to infection route,
other factors such as mouse strain, Mtb strain and/or dosage of
the COXi drug could also have an impact on the outcome.
Indeed, two previous studies have shown that aspirin and ibu-
profen had no effect on bacterial burden as stand-alone treatment
in aerosol infected BALB/c mice, whereas they had variable effects
in enhancing/antagonizing treatment with pyrazinamide and
isoniazide10,11.
As the innate inﬂammatory response was not affected by COXi
treatment in the aerosol model, we hypothesized that the
increased bacterial burden in treated animals could be associated
with changes in adaptive immunity. In support of this, we showed
that COXi-treated mice were more susceptible to re-infection
compared to untreated mice, indicating that memory immunity
was impaired by the treatment. Recent mouse studies have
focused on lung-homing as a key aspect of adaptive immunity
towards Mtb22–24, but no effect on the frequency of lung-homing
CD4 T cells as determined by in vivo intravascular staining was
observed by COXi treatment in the present study. Instead, there
was a substantial decrease in T-bet expression of CD4 T cells,
which was associated with a drop in IFNγ production. It is well
known that cyclooxygenases and their metabolites, in particular
PGE2, regulate a multitude of functions in T cell differentiation
and effector function25,31. Several studies have demonstrated that
micromolar-range concentrations of PGE2 inhibit Th1 differ-
entiation via downregulation of the IL-12 signaling pathway32–34,
but other studies have shown that PGE2, in combination with
TNFα, promote Th1-inducing dendritic cells and that nanomolar
concentrations of PGE2 potentiate Th1 differentiation through
downstream signaling of the PGE2 receptor 4 (EP4)35,36. In our
studies, we observed that COXi treatment decreased Th1 differ-
entiation with little or no impact on IL-12 production, which is
most consistent with a model where PGE2 favors Th1 differ-
entiation. Whether the observed treatment effect on Th1 differ-
entiation and effector-function was caused by changes in the
downstream signaling pathway of EP4, or if other environmental
mechanisms were responsible, should be the focus of future
mechanistic studies. We did not perform a detailed analysis of the
CD8 T cells and more work is needed to investigate the potential
inﬂuence of celecoxib on this subset.
T-bet expression of CD4 T cells plays a key role for the
development and maintenance of Th1 mediated protection
against Mtb and mice deﬁcient in T-bet as well as IFNγ are highly
susceptible to Mtb infection37,38. However, more recently it has
also been demonstrated that T-bethi Th1 cells are less protective
than T cells with intermediate T-bet expression and that CD4 T
cell derived IFNγ plays a less pronounced role against pulmonary
Mtb infection39,40. Hence, in the ﬁnal experiment, we investigated
whether the observed reduction in T-bet expression after COXi
treatment was associated with a decreased protective capacity of
the CD4 T cell population. We observed that CD4 T cells from
celecoxib-treated donors produced less IFNγ than CD4 T cells
from untreated control animals and that they were less efﬁcient at
controlling bacterial replication when transferred to infected
TCRα−/− recipients. Altogether, this shows that COXi treatment
can impede adaptive immunity against Mtb, possibly by manip-
ulating the Th1 function of CD4 T cells.
To our knowledge, this is the ﬁrst demonstration that COXi
can affect adaptive immune responses negatively in the context of
Mtb infection. Our data do not rule out that other mechanisms
also may play a role in our model and that COXi treatment
during active TB can alleviate excessive inﬂammation when
present, which is in line with decreased bacterial burden in
COXi-treated mice after i.v. infection reported herein and by
others12–14. Instead, we state that our data sheds light on a
potential unidentiﬁed risk of COXi treatment.
Although translating ﬁndings in mouse models to humans
comes with multiple limitations, the frequent use of NSAID to
alleviate TB symptoms calls for conﬁrmatory studies in humans.
There are no studies exploring the effects of NSAIDs on cure/
relapse during active TB, but a few observational studies have
investigated a possible association between the use of NSAIDs
and development of active TB. Two old case reports and a small
retrospective case-control study express a concern for risk of
progression to TB in patients using NSAIDs although these
provide weak, if any evidence for this concern41–43. However, a
recent population-wide retrospective case-control study from
Taiwan suggested an association between NSAID prescriptions
and increased risk of TB, but was unable to demonstrate an
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association for COXi speciﬁcally in the adjusted analysis44. This
study was corroborated by another Taiwanese study focusing on
patients with psoriasis45, but a similar association was not found
in a Canadian study of patients with rheumatoid arthritis46.
Although some of these studies express concern that NSAIDs
increase the risk of developing TB, retrospective case-control
studies are associated with several limitations. Most importantly,
they are unable to demonstrate causality and do not control for
protopathic bias (e.g. NSAIDs were prescribed to alleviate
symptoms of undiagnosed/subclinical TB prior to diagnosis of
active TB). In the future, it would therefore be essential to
establish whether there is a causative relationship between the use
of NSAIDs/COXi and progression to active TB, and subsequently
to investigate in more detail how altered eicosanoid balances
inﬂuence innate as well as adaptive immune responses. Currently,
there are registered three clinical trials exploring the effect of
NSAIDs on different aspects of active TB (NCT02060006,
NCT02781909 and NCT02503839).
In conclusion, we have identiﬁed a potential new risk that
treatment with COXi during Mtb infection impairs CD4 T cell
mediated immunity by decreasing Th1 differentiation and effec-
tor function. While it is evident how this could play a role in
latent TB infection, where adaptive immunity is responsible for
controlling the infection, it is less clear for active TB, where
adaptive immunity has already failed and antibiotic therapy
restricts bacterial replication. We suggest careful investigation of
the impact of COXi on both active and latent TB in diverse
animal models as well as clinical trials.
Materials and methods
Mice. Five to eight-week-old female C3HeB/FeJ (The ‘Jackson’ Laboratories, Bar
Harbor, ME), CB6F1 hybrid mice (female BALB/c ×male C57BL/6, ‘Envigo’
Laboratories, The Netherlands), C57BL/6 (Charles River Laboratories, Wilmington,
MA) and B6.129S2-Tcratm1Mom/J (Jackson), were purchased and randomly
assigned to cages at the animal facility at Statens Serum Institut (SSI) upon arrival.
Animals were allowed to rest for 1 week before any experimental manipulation and
they were allowed free access to water and food throughout the experiment. Mice
were weighed throughout the experiments to ensure equal food intake. Experi-
ments were conducted in accordance with the regulations set forward by the
national animal protection committee and in compliance with European Com-
munity Directive 2010/63. A local animal protection committee at SSI, IACUC,
headed by DVM Kristin Engelhart Illigen, approved all experiments.
Experimental models. Low-dose aerosol infection model: Female CB6F1 mice
were infected by the aerosol route with ~25–50 CFU Mtb Erdman. Four weeks post
challenge, mice were put on an 8-week course of normal chow (2916 Teklad Global
16% Protein Rodent Diet, Envigo) or chow containing 500 mg/kg celecoxib (LC
Laboratories, Cat. No. C-1502) (Fig. 1 and Fig. 3). In one experiment (indicated in
the text), mice were treated with oral ibuprofen (Nurofen orange ﬂavor, purchased
from pharmacy) in a daily dose of 80 mg/kg (2.24 mg/mice), which the mice was
offered to eat from a pipette tip (Fig. 2).
High-dose aerosol infection model: Female CB6F1 mice were infected by the
aerosol route with ~150–300 CFU Mtb Erdman. Three weeks post challenge, mice
were treated with ibuprofen (Nurofen orange ﬂavour, purchased from pharmacy)
administered orally from a pipette tip in a daily dose of 80 mg/kg. The health status
of individual mice was monitored according to a validated clinical scoring system
(0–5) derived from the consolidation Act on Experimental Animals (BEK-88
30.01.2013) and mice were euthanized when they reached deﬁned humane
endpoints. The staff had several years of experience with the use of this scoring
system: The mouse was unaffected (0), the mouse was slightly affected (slower
movement and possibly slight bristle fur) (1), the mouse was obviously affected
(immobile when inspected from outside the cage but mobile when the cage was
moved, possible bristled fur, slightly changed breathing, eyes slightly closed,
buckled back) (2), the mouse was moderately affected (mobile when physically
touched, bristled fur, clearly changed breathing, eyes half closed, buckled back) (3),
the mouse was heavily affected (almost immobile when physically touched, bristled
fur, changed breathing, eyes closed) (4), the mouse was immobile and cold (5). The
mice were euthanized when they reached a score of 2 or over.
Intravenous infection model: Female C3HeB/FeJ or CB6F1 mice were i.v.
infected with 5.0 × 104 CFU Mtb H37Rv or Mtb Erdman, respectively. Three weeks
post infection, mice were treated with ibuprofen (Nurofen orange ﬂavour,
purchased from pharmacy) administered orally from a pipette tip in a daily dose of
80 mg/kg for 1 week (Fig. 2).
Re-infection model: Female CB6F1 mice were infected with ~25–50 CFU Mtb
Erdman by the aerosol route. Four weeks after infection mice were fed with
celecoxib chow for 8 weeks. Starting at 10 weeks post infection, mice were put on a
course of isoniazid (0.1 g L−1) and rifabutin (0.1 g L−1) (Becton Dickinson) in the
drinking water ad libitum for 12 weeks. After 2 weeks of rest, to wash out
antibiotics, mice were re-challenged with ~50–100 CFU of Mtb Erdman 24 weeks
post the ﬁrst infection (Fig. 3).
Adoptive transfer model: 7- to 8week-old female C57BL/6J wild type mice were
infected with ~25–50 CFU Mtb Erdman by the aerosol route. After 4 weeks of
celecoxib-treatment, CD4 T-cells were puriﬁed from the spleen, tracheobronchial
and mediastinal lymph nodes by negative selection (EasySepTM Mouse CD4+ T
cell Isolation Kit). A total of 9.5 × 106 CD4 T cells in 200 µl from either C57BL/6J
wild type mice or celecoxib-treated mice were transferred by i.v. injection to T cell
receptor α-deﬁcient B6.129S2-Tcratm1Mom/J recipient mice that were infected
1 week earlier with Mtb Erdman. A control group did not receive any T cells
(Fig. 4).
Sample size. In the low-dose aerosol challenge model (incl. the adoptive transfer
study), we powered the experiments for detecting a treatment effect 0.5 log10 CFU
reduction in lungs compared to non-treated controls with a type I error rate of 5%
(α= 0.05), a power of 80% and standard deviation of 0.35 log10 CFU (based on
previous experiments). This resulted in n= 8 mice per group for primary analysis.
We had no prior experience with the intravenous infection model and no power
calculations were made. To ensure conclusive results, we increased the sample size
to n= 13. Similarly, in the high-dose aerosol challenge model, a large sample size of
n= 32 was selected due to the binary endpoint of dead/alive. In the re-infection
model, we powered the experiment for detecting a treatment effect of 0.5 log10
CFU reduction compared to non-treated controls with a type I error rate of 5%
(α= 0.05), a power of 80% and standard deviation of 0.5 log10 CFU. This resulted
in n= 16 mice per group for primary analysis.
Mtb infections and CFU enumeration. Mtb Erdman (TMC 107, ATCC) or Mtb
H37Rv (ATCC) were grown to log phase in 7H9 medium enriched with Mid-
dlebrook ADC (BD Pharmingen, San Diego, CA, USA) without Tween. Log-phase
bacteria were aliquoted and stored at −80 °C. For in vivo infection, vials of Mtb
Erdman or H37Rv were thawed and sonicated for 5 min in a water bath. Fur-
thermore, bacterial clumps were removed by dispersing the suspensions through a
syringe.
For i.v. infections, mice were infected with 5.0 × 104 CFU/mice in 100 µl
injected into the tail vein. For aerosol infections, the inoculum was aerosolised for
inhalation using a Biaera exposure system controlled via AeroMP software (Biaera,
Hagerstown, MD, USA). The standard dose used in this study results in
approximately 25–50 CFU/mouse.
The bacterial burden in lung was determined by homogenising the left lung lobe
using M-tubes and a Miltenyi AutoMACS Dissociator (Miltenyi, Germany). The
homogenate was serially diluted in 1x PBS containing panta (BD) and plated onto
7H11 MiddleBrook agar plates (BD). Colony forming units (CFU’s) were
enumerated after 2 weeks of incubation at 37 °C, 5% CO2.
Preparation of tissue and single cell suspension. Right lung lobes and spleens
were aseptically removed from euthanatized mice and put into 2.5 mL cold RPMI.
Lungs were mildly homogenized using T-tubes GentleMACS (Miltenyi Biotec),
lung supernatants were harvested for cytokine analysis, right before digesting the
lungs using collagenase IV (Sigma-Aldrich) for 30–60 min at 37 °C. Single cell
suspensions of spleenocytes or lung cells were obtained by passing the suspension
through 100 μm cell strainers. Lung and spleen cells were counted with an auto-
matic NucelocounterTM (Chemotec). Blood samples were taken by cardiac
puncture in tubes containing EDTA and plasma samples were harvested for
cytokine analysis. Cells were washed twice in RPMI before direct staining for
tetramers and surface markers or overnight stimulation for ICS analysis.
Intravascular staining of T cells. Anti-mouse CD45.2 FITC (clone 104; BD) was
diluted 1:50 in 1x PBS, 2.5 μg/mouse was given in 250 μl i.v. via the tail vein 3–6
min prior to organ harvest to distinguish parenchymal-localized (iv−) and
vasculature-associated (iv+) T cells.
Staining for ﬂow cytometry. Prior to surface staining, cells were Fc receptor
blocked with anti-CD16/32 either in combination with the tetramer stain or not.
The ESAT-6 tetramer (I-Ab:ESAT-64-17-PE) and the negative control (I-Ab:hCLIP-
PE) were provided by the NIH tetramer facility (Atlanta, GA, USA). Cells were
stained with tetramers for 30 min at 37 °C. For the analysis of innate cells, surface
staining with the following markers: anti-CD3-Bv650, Ly-6G-PE, Ly-6C-FITC,
CD11b conjugated to APC–Cy7 or PerCP–Cy5.5, CD11c-APC, CD86-PE-Cy7 and
MHCII-PerCP–Cy5.5 was performed at 4 °C. For intracellular cytokine staining, a
total of 1–2 × 106 spleen or lung cells were stimulated in vitro for 1 h in RPMI+
10% FCS containing 1 μg/ml anti-CD28 and anti-CD49d with or without 5 μg of
ESAT-6 pepmix followed by 5 h in the presence of 10 μg/ml brefeldin A (Sigma-
Aldrich) at 37 °C. Cells were kept at 4 °C overnight. Following, cells were washed
once in FACS buffer (1x PBS containing 1% FCS) and surface stained using anti-
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CD3-Bv650, anti-CD4-Bv510, anti-CD44-Bv786, anti-PD-1-Bv421 and anti-
KLRG1-Bv711 at 4 °C for 15–30 min. Cells were washed in FACS buffer twice and
permeabilized using the Cytoﬁx/Cytoperm kit (BD) according to the manu-
facturer’s instructions. Following two washings steps, cells were stained intra-
cellularly with anti–IFNγ PE-Cy7, anti–TNF–PE, anti-IL-2–APC–Cy7, anti-IL-
17A–PerCP–Cy5.5 for 20–30 min. For transcription factor staining, the FoxP3/
transcription factor buffer set (eBioscience) was used with anti-T-bet-ef660,
RORγt-PE-CF594, FoxP3-FITC and GATA3-BV421. Cells were subsequently
washed, resuspended in FACS buffer and analysed with a LSR FACS Fortessa (BD).
Dead cells were excluded from the analysis by the ﬁxable viability ef780. All ﬂow
cytometry data was analysed with FlowJo software v.10 (Tree Star, Ashland,
OR, USA).
Cytokine multiplex assay. The levels of pro-inﬂammatory cytokines in plasma
samples and lung supernatants were evaluated using a multiplex Meso Scale Dis-
covery assay (MSD). The pro-inﬂammatory Panel 1 (Mouse) 7-plex MSD assay
measuring IL-1β, KC/GRO, IL-6, IL-12p70, IFNγ, TNFα, and IL-10 was performed
according to the manufacturer’s instructions. A Sector Imager 2400 system (Meso
Scale Discovery) was used for analysing the plates. The pro-inﬂammatory cytokine
concentrations in unknown samples were calculated by a 4-parameter logistic non-
linear regression analysis of the standard curve. Data on IL-10 is not shown as
levels were below detection limit.
Immunohistochemistry and iNOS staining. Right lobes were perfused with- and
immersed in 4% phosphate-buffered formaldehyde (pH. 7.3) and stored at 4 °C.
Lungs were further processed at BioSiteHisto (Helsinki, Finland). Each lobe was
parafﬁn-embedded in blocks and sliced in four-millimeter thick sections using
water fall rotation microtomes. Each sample was stained with haematoxylin and
eosin. Inducible nitric oxide synthase (iNOS) was detected by immunohis-
tochemistry using a polyclonal rabbit antibody in 1:200 dilution (Cat. # ab15323,
BioSiteHisto). Brieﬂy, parafﬁn sections were heated on a heating plate (+65 °C,
20 min.) to get better adherence between slide and section. Deparafﬁnisation was
done by incubation in xylene for 10 min. After that, slides were moved into Leica
Autostainer (Labvision) for additional parafﬁn removing, rehydration, and
immunohistochemical staining, counterstaining, dehydration and mounting. Heat
induced epitope retrieval was performed using a PT-module (Lab Vision) in TRIS-
EDTA buffer pH9 at 95–100 °C. A 15min heating was used to reach the correct
temperature followed by 20 min epitope retrieval in the mentioned temperature.
Changes in histopathology was assessed by a skilled pathologist that was blinded
for both group association and treatment.
Statistics and reproducibility. The effect of COXi treatment was assessed by an
unpaired t-test between treated and non-treated animals unless otherwise indi-
cated. Comparison of pro-inﬂammatory cytokines measured by multiplex was
performed using an ANOVA followed by the Benjamini-Hochberg method to
control the false discovery rate during multiple comparisons. For these compar-
isons we report the q values, which is the adjusted p value. A chi-square test was
used to calculate the p value in the assessment of survival after high-dose aerosol
challenge. A value of p < 0.05 was considered signiﬁcant. All statistical analyses
were carried out in GraphPad Prism version 7.04 (GraphPad Software Inc.).
Blinding. The investigator was not involved in data collection. Organ homo-
genization, plating and CFU counting was performed by an experienced technician,
who was not involved in study design and/or data analysis. Changes in histo-
pathology was performed by a skilled pathologist who was blinded for both group
association and treatment. The investigator was not blinded during data analysis
and interpretation.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The datasets that support the ﬁnding of this study are available from the corresponding
author on reasonable request.
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